According to a recent LinkedIn post from Tastewise, the growing use of GLP-1 medications in the U.S. appears to be shifting consumer behavior toward protein-centric food choices. The post cites an estimate that among 13 million Americans using GLP-1 drugs, 8 in 10 reportedly prioritize protein as the main filter when deciding what to eat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post suggests this shift is already influencing category-level portfolio strategies, particularly in snacks and desserts. Traditional snack and dessert formats are described as showing negative movement, while protein-forward offerings in the same categories are said to be generating double-digit growth.
According to the post, brands that arrive at retail buyer meetings with real-time data on these preference shifts may be better positioned to gain expanded shelf space. The post further implies that having early clarity on evolving consumer demand can strengthen sell-in narratives before changes become visible in velocity data, potentially benefiting suppliers able to act quickly on such insights.
For investors, the content points to a possible tailwind for companies aligned with high-protein innovation and a headwind for legacy indulgent formats that do not adapt. It also underscores potential demand for data and analytics solutions that track rapid behavioral changes tied to GLP-1 usage, a niche in which Tastewise appears to be positioning its capabilities within the broader food and beverage ecosystem.